News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
469,114 Results
Type
Article (28869)
Company Profile (70)
Press Release (440175)
Multimedia
Podcasts (79)
Webinars (7)
Section
Business (144593)
Career Advice (1533)
Deals (24720)
Drug Delivery (60)
Drug Development (51889)
Employer Resources (104)
FDA (11428)
Job Trends (10458)
News (236586)
Policy (22116)
Tag
Academia (1771)
Academic (1)
Accelerated approval (4)
Adcomms (12)
Allergies (57)
Alliances (40313)
ALS (59)
Alzheimer's disease (1037)
Antibody-drug conjugate (ADC) (74)
Approvals (11459)
Artificial intelligence (212)
Autoimmune disease (14)
Automation (13)
Bankruptcy (227)
Best Places to Work (8671)
BIOSECURE Act (8)
Biosimilars (57)
Biotechnology (48)
Bladder cancer (62)
Brain cancer (17)
Breast cancer (216)
Cancer (1723)
Cardiovascular disease (125)
Career advice (1303)
Career pathing (23)
CAR-T (92)
Cell therapy (302)
Cervical cancer (17)
Clinical research (41497)
Collaboration (691)
Compensation (160)
Complete response letters (9)
COVID-19 (2519)
CRISPR (27)
C-suite (158)
Cystic fibrosis (64)
Data (1670)
Decentralized trials (2)
Denatured (24)
Depression (27)
Diabetes (198)
Diagnostics (6373)
Digital health (13)
Diversity (3)
Diversity, equity & inclusion (31)
Drug discovery (89)
Drug pricing (57)
Drug shortages (19)
Duchenne muscular dystrophy (65)
Earnings (62186)
Editorial (34)
Employer branding (13)
Employer resources (92)
Events (68614)
Executive appointments (493)
FDA (12347)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (5)
Funding (519)
Gene editing (62)
Generative AI (21)
Gene therapy (225)
GLP-1 (470)
Government (3406)
Grass and pollen (4)
Guidances (56)
Healthcare (12821)
Huntington's disease (12)
IgA nephropathy (18)
Immunology and inflammation (81)
Indications (23)
Infectious disease (2661)
Inflammatory bowel disease (98)
Inflation Reduction Act (8)
Influenza (54)
Intellectual property (73)
Interviews (281)
IPO (12028)
IRA (26)
Job creations (2180)
Job search strategy (1091)
Kidney cancer (7)
Labor market (21)
Layoffs (263)
Leadership (16)
Legal (5213)
Liver cancer (44)
Lung cancer (245)
Lymphoma (116)
Machine learning (4)
Management (36)
Manufacturing (225)
MASH (51)
Medical device (8771)
Medtech (8775)
Mergers & acquisitions (13168)
Metabolic disorders (470)
Multiple sclerosis (59)
NASH (10)
Neurodegenerative disease (55)
Neuropsychiatric disorders (14)
Neuroscience (1391)
NextGen: Class of 2025 (4227)
Non-profit (3021)
Now hiring (10)
Obesity (233)
Opinion (166)
Ovarian cancer (60)
Pain (59)
Pancreatic cancer (59)
Parkinson's disease (100)
Partnered (17)
Patents (171)
Patient recruitment (71)
Peanut (29)
People (36588)
Pharmaceutical (14)
Pharmacy benefit managers (8)
Phase I (12899)
Phase II (17819)
Phase III (14463)
Pipeline (1016)
Policy (102)
Postmarket research (1861)
Preclinical (5567)
Press Release (47)
Prostate cancer (106)
Psychedelics (18)
Radiopharmaceuticals (221)
Rare diseases (264)
Real estate (3504)
Recruiting (40)
Regulatory (15058)
Reports (30)
Research institute (1687)
Resumes & cover letters (230)
Rett syndrome (3)
RNA editing (4)
RSV (50)
Schizophrenia (48)
Series A (81)
Series B (52)
Service/supplier (5)
Sickle cell disease (39)
Special edition (7)
Spinal muscular atrophy (73)
Sponsored (22)
Startups (2185)
State (1)
Stomach cancer (9)
Supply chain (39)
Tariffs (24)
The Weekly (53)
Vaccines (805)
Venture capitalists (19)
Weight loss (141)
Women's health (20)
Worklife (12)
Date
Today (123)
Last 7 days (603)
Last 30 days (1884)
Last 365 days (23577)
2025 (7883)
2024 (24930)
2023 (28158)
2022 (36913)
2021 (40065)
2020 (38400)
2019 (31173)
2018 (23495)
2017 (22401)
2016 (21746)
2015 (25430)
2014 (20874)
2013 (18128)
2012 (18428)
2011 (18234)
2010 (17047)
Location
Africa (678)
Alabama (43)
Alaska (5)
Arizona (135)
Arkansas (10)
Asia (27051)
Australia (4566)
California (4111)
Canada (1399)
China (348)
Colorado (208)
Connecticut (219)
Delaware (97)
Europe (62288)
Florida (683)
Georgia (171)
Idaho (27)
Illinois (370)
India (21)
Indiana (235)
Iowa (7)
Japan (124)
Kansas (70)
Kentucky (11)
Louisiana (4)
Maine (64)
Maryland (672)
Massachusetts (3097)
Michigan (175)
Minnesota (230)
Mississippi (2)
Missouri (49)
Montana (17)
Nebraska (17)
Nevada (48)
New Hampshire (46)
New Jersey (1373)
New Mexico (24)
New York (1279)
North Carolina (760)
North Dakota (8)
Northern California (1774)
Ohio (137)
Oklahoma (11)
Oregon (20)
Pennsylvania (970)
Puerto Rico (2)
Rhode Island (24)
South America (858)
South Carolina (17)
Southern California (1571)
Tennessee (81)
Texas (685)
United States (16420)
Utah (150)
Virginia (101)
Washington D.C. (46)
Washington State (385)
West Virginia (2)
Wisconsin (47)
469,114 Results for "longhorn vaccines and diagnostics llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Longhorn Vaccines and Diagnostics Presents Compelling Data on LHNVD-303 Vaccine for Sepsis Related to Bacterial Infections at the World Vaccine Congress
April 25, 2025
·
4 min read
Press Releases
Longhorn Vaccines and Diagnostics to Present Data on Single and Dual Peptide Universal Influenza Candidates at ESCMID 2025
April 9, 2025
·
3 min read
BioCapital
Longhorn Vaccines and Diagnostics to Present Data on LHNVD-105, a Universal Vaccine Candidate, at ECCMID 2024
Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present three abstracts at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024.
April 11, 2024
·
2 min read
Press Releases
Longhorn Vaccines and Diagnostics Composite Peptide Vaccine Combats Sepsis Related to Antimicrobial Resistant Tuberculosis
November 13, 2024
·
3 min read
BioCapital
Longhorn Vaccines and Diagnostics Presents New Data on its Best-In-Class Infectious Disease Vaccine and Antibody Portfolio at ECCMID 2024
Longhorn Vaccines and Diagnostics presented positive data from three key studies of its infectious disease franchise at the European Congress of Clinical Microbiology and Infectious Diseases 2024.
April 27, 2024
·
5 min read
BioCapital
Longhorn Vaccines and Diagnostics Presents at World Vaccine Congress on Advantages of Single Peptide Vaccine for Broad Coverage of Human and Avian Influenza Viruses
Longhorn Vaccines and Diagnostics Congress all day April 2-4, 2024 on a mice study that examined LHNVD-110, a novel, unconjugated single peptide vaccine comprised of multiple epitopes to broadly target human and influenza viruses.
April 2, 2024
·
4 min read
Press Releases
Longhorn Vaccines and Diagnostics Highlights New Data for LHNVD-303 its Bacterial Sepsis Vaccine at IDWeek 2024
October 17, 2024
·
3 min read
Press Releases
Longhorn Vaccines and Diagnostics to Present Data on Antimicrobial Resistant Sepsis Vaccine LHNVD-303 at The Union World Conference on Lung Health 2024
November 7, 2024
·
3 min read
Press Releases
Longhorn Vaccines and Diagnostics to Present Data on Universal Influenza Vaccine LHNVD-110 and Antimicrobial Resistant Sepsis Vaccine LHNVD-303 at IDWeek 2024
October 9, 2024
·
3 min read
BioCapital
Longhorn Vaccines and Diagnostics Presents Targeted Vaccine Approach for Mycobacterium Tuberculosis with LHNVD-301
Longhorn Vaccines and Diagnostics today presented new data from an animal study of LHNVD-301, the company’s lead tuberculosis vaccine candidate.
November 15, 2023
·
4 min read
1 of 46,912
Next
